VTRS - Viatris Inc Stock Price, Fair Value and News

11.55USD+0.19 (+1.67%)Market Closed

Market Summary

USD11.55+0.19

Market Closed

1.67%

VTRS Stock Price

View Fullscreen

VTRS RSI Chart

VTRS Valuation

Market Cap

13.5B

Price/Earnings (Trailing)

246.63

Price/Sales (Trailing)

0.87

EV/EBITDA

8.16

Price/Free Cashflow

5.57

VTRS Price/Sales (Trailing)

VTRS Profitability

EBT Margin

1.32%

Return on Equity

0.27%

Return on Assets

0.11%

Free Cashflow Yield

17.96%

VTRS Fundamentals

VTRS Revenue

Revenue (TTM)

15.4B

Rev. Growth (Yr)

-1%

Rev. Growth (Qtr)

-2.65%

VTRS Earnings

Earnings (TTM)

54.7M

Earnings Growth (Yr)

-175.71%

Earnings Growth (Qtr)

-330.88%

Breaking Down VTRS Revenue

Last 7 days

2.2%

Last 30 days

-4.0%

Last 90 days

-3.1%

Trailing 12 Months

21.8%

How does VTRS drawdown profile look like?

VTRS Financial Health

Current Ratio

1.67

Debt/Equity

0.79

Debt/Cashflow

0.17

VTRS Investor Care

Dividend Yield

4.23%

Dividend/Share (TTM)

0.48

Buy Backs (1Y)

0.77%

Diluted EPS (TTM)

0.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	15.8B	15.6B	15.5B	15.4B
2022	17.6B	17.2B	16.7B	16.3B
2021	13.8B	15.6B	17.2B	17.9B
2020	11.6B	11.7B	11.8B	11.9B
2019	0	0	0	11.5B
2018	0	0	0	11.4B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Viatris Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	mauro anthony	sold	-3,023,700	12.0948	-250,000	see remarks
Mar 05, 2024	campbell paul	sold	-300,272	12.33	-24,353	see remarks
Mar 05, 2024	lyons dillon joellen	sold	-247,200	12.36	-20,000	-
Mar 04, 2024	mauro anthony	acquired	-	-	39,784	see remarks
Mar 04, 2024	ni xiangyang (sean)	acquired	-	-	8,222	president, greater china
Mar 04, 2024	campbell paul	acquired	-	-	19,427	see remarks
Mar 04, 2024	malik rajiv	sold (taxes)	-481,187	12.36	-38,931	president
Mar 04, 2024	campbell paul	sold (taxes)	-105,159	12.36	-8,508	see remarks
Mar 04, 2024	mauro anthony	sold (taxes)	-213,865	12.36	-17,303	see remarks
Mar 04, 2024	cuneo andrew	sold (taxes)	-37,500	12.36	-3,034	see remarks

Which funds bought or sold VTRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Creative Capital Management Investments LLC	reduced	-75.38	-1,026	382	-%
Apr 23, 2024	REGIONS FINANCIAL CORP	reduced	-5.39	8,344	201,941	-%
Apr 23, 2024	WETZEL INVESTMENT ADVISORS, INC.	reduced	-31.59	-2,872	7,128	-%
Apr 23, 2024	AMALGAMATED BANK	added	36.82	1,660,000	4,923,000	0.04%
Apr 23, 2024	Summit Trail Advisors, LLC	added	13.41	41,631	207,947	0.01%
Apr 23, 2024	GODSEY & GIBB, INC	added	5.58	414	2,938	-%
Apr 23, 2024	Livforsakringsbolaget Skandia, Omsesidigt	unchanged	-	2,017	21,868	-%
Apr 23, 2024	EADS & HEALD WEALTH MANAGEMENT	added	1.62	15,000	144,000	0.07%
Apr 23, 2024	HALL LAURIE J TRUSTEE	reduced	-1.77	2,000	32,000	0.01%
Apr 23, 2024	CIGNA INVESTMENTS INC /NEW	reduced	-2.82	10,000	150,000	0.03%

Are Funds Buying or Selling VTRS?

Are funds buying VTRS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VTRS

No. of Funds

Unveiling Viatris Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.86%	142,262,690	SC 13G/A
Feb 09, 2024	davis selected advisers	5.2%	62,661,728	SC 13G
Jan 30, 2024	state street corp	5.17%	61,969,119	SC 13G/A
Jan 26, 2024	blackrock inc.	7.7%	92,337,568	SC 13G/A
Feb 09, 2023	vanguard group inc	12.31%	149,318,666	SC 13G/A
Feb 07, 2023	state street corp	5.10%	61,903,672	SC 13G
Jan 31, 2023	blackrock inc.	7.7%	93,214,306	SC 13G/A
Feb 04, 2022	wellington management group llp	4.57%	55,233,099	SC 13G/A
Feb 03, 2022	blackrock inc.	7.2%	86,554,658	SC 13G/A
Feb 04, 2021	wellington management group llp	5.74%	69,811,210	SC 13G

Recent SEC filings of Viatris Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	3	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 11, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Viatris Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	360.2B	85.2B	-3.67%	-8.64%	10.25	4.23	6.46%	95.94%
MRK	321.4B	60.1B	2.46%	9.45%	880.53	5.35	1.40%	-97.49%
PFE	148.6B	46.5B	-3.80%	-34.05%	-107.04	3.19	42.59%	-114.62%
AMGN	146.6B	28.2B	-0.95%	11.90%	21.82	5.2	7.09%	2.52%
GILD	83.5B	27.1B	-7.68%	-22.69%	14.74	3.08	-0.60%	23.36%
TEVA	14.6B	15.8B	-6.26%	55.93%	-25.32	0.92	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	-2.65%	-15.52%	-325.34	0.89	4.58%	90.97%
ALKS	4.1B	1.7B	-11.07%	-16.83%	11.39	2.44	49.61%	324.78%
BHC	3.1B	8.8B	-10.77%	12.83%	-5.27	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-6.43%	-0.05%	14.31	3.05	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-20.35%	-21.70%	-4.05	1.92	24.65%	80.36%
TXMD	21.7M	1.3M	-17.90%	-49.19%	-2.11	16.65	-98.14%	-109.18%
ACRX	16.3M	-	-14.29%	38.83%	-0.89	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-32.73%	-94.43%	-0.18	0.13	80.00%	43.08%
ACOR	645.9K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Viatris Inc News

Latest updates

Viatris Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Revenue	-2.7%	3,837	3,942	3,919	3,729	3,876	4,078	4,117	4,192	4,342	4,537	4,578	4,430	3,624	2,972	2,731	2,619	-	-
Gross Profit	-5.6%	1,597	1,691	1,609	1,542	1,274	1,748	1,703	1,771	1,546	1,574	1,328	1,127	706	1,159	1,026	906	-	-
Operating Expenses	65.5%	2,051	1,240	1,239	1,142	1,475	1,188	1,155	1,064	1,624	1,217	1,376	1,394	1,588	807	892	721	-	-
S&GA Expenses	52.4%	1,606	1,054	1,032	959	1,265	1,017	981	915	1,083	1,055	1,205	1,187	1,361	658	719	605	-	-
R&D Expenses	-100.0%	-	211	208	183	-	175	163	142	267	152	148	184	155	130	156	114	-	-
EBITDA Margin	-41.9%	0.23*	0.39*	0.39*	0.39*	0.40*	0.28*	0.28*	0.27*	0.25*	0.23*	0.21*	0.19*	-	-	-	-	-	-
Interest Expenses	-0.4%	141	142	144	147	147	153	146	146	148	152	167	169	144	117	116	120	-	-
Income Taxes	-226.6%	-89.40	71.00	69.00	98.00	458	73.00	75.00	128	60.00	-111	60.00	596	-97.70	56.00	-19.40	10.00	-	-
Earnings Before Taxes	-312.6%	-855	402	333	323	1,469	428	389	528	-203	200	-219	-441	-1,013	242	20.00	31.00	-	-
EBT Margin	-92.0%	0.01*	0.16*	0.16*	0.17*	0.17*	0.07*	0.05*	0.02*	-0.04*	-0.09*	-0.09*	-0.09*	-	-	-	-	-	-
Net Income	-330.9%	-765	332	264	225	1,011	354	314	399	-263	312	-279	-1,037	-915	186	39.00	21.00	-	-
Net Income Margin	-97.0%	0.00*	0.12*	0.12*	0.12*	0.13*	0.05*	0.04*	0.01*	-0.07*	-0.11*	-0.13*	-0.13*	-	-	-	-	-	-
Free Cashflow	-57.5%	314	738	447	923	-11.10	765	719	1,074	326	965	470	799	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-2.2%	47,686	48,743	48,695	49,290	50,022	48,663	51,125	53,467	54,843	56,070	57,984	58,979	61,553	11,413	11,412	31,256
Current Assets	18.7%	12,976	10,932	9,778	9,630	10,635	10,488	11,177	11,744	10,903	11,308	11,750	12,319	12,868	11,413	11,412	6,757
Cash Equivalents	-24.3%	992	1,310	629	507	1,260	647	665	752	701	757	674	807	850	665	324	491
Inventory	-5.5%	3,470	3,672	3,642	3,664	3,520	3,380	3,613	3,797	3,978	4,082	4,488	4,942	5,472	-	-	2,671
Net PPE	-5.7%	2,760	2,927	2,983	3,008	3,025	3,039	3,084	3,150	3,189	3,114	3,171	3,247	3,460	-	-	2,150
Goodwill	-4.0%	9,867	10,278	10,533	10,573	10,426	10,055	10,523	10,979	12,114	12,170	11,990	11,907	12,347	-	-	9,591
Liabilities	-2.4%	27,218	27,877	27,852	28,362	28,950	29,480	31,320	33,019	34,350	34,929	36,777	37,565	38,599	11,614	11,413	19,372
Current Liabilities	13.8%	7,777	6,834	6,524	6,108	6,746	6,521	7,681	9,643	9,884	10,104	10,133	9,978	10,563	79.00	28.00	5,569
Short Term Borrowings	-100.0%	-	0.00	23.00	205	-	500	1,020	655	1,493	1,707	1,301	37.00	1,101	-	-	-
Long Term Debt	-5.2%	16,188	17,077	17,246	18,069	18,015	18,725	19,206	18,763	19,717	19,854	20,917	22,102	22,429	11,535	11,385	11,214
LT Debt, Current	48.6%	1,943	1,307	1,334	509	1,259	764	768	2,606	1,878	1,908	2,184	2,300	2,309	-	-	1,508
LT Debt, Non Current	-5.2%	16,188	17,077	17,246	18,069	18,015	18,725	19,206	18,763	19,717	19,854	20,917	22,102	22,429	11,535	11,385	11,214
Shareholder's Equity	-1.9%	20,467	20,866	20,843	20,928	21,072	19,182	19,805	20,448	20,493	21,141	21,207	21,415	22,954	12,548	11,746	11,884
Retained Earnings	-16.4%	4,640	5,553	5,369	5,253	5,176	4,313	4,107	3,942	3,689	4,087	3,910	4,324	5,361	-170	-0.90	6,031
Additional Paid-In Capital	0.3%	18,815	18,761	18,719	18,680	18,646	18,617	18,586	18,555	18,536	18,514	18,490	18,465	18,439	-31.00	-0.30	8,644
Shares Outstanding	-	-	-	-	1,203	1,212	1,212	1,211	1,211	1,209	1,209	1,208	1,208	601	517	-	-
Float	-	-	-	11,937	-	-	-	12,662	-	-	-	17,238	-	-	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-42.5%	479	834	515	971	143	869	803	1,139	523	1,086	559	849	36.00	525	380	291	-	-	-	-	-
Share Based Compensation	29.5%	56.00	43.00	39.00	43.00	30.00	29.00	29.00	28.00	23.00	25.00	31.00	33.00	29.00	15.00	15.00	19.00	-	-	-	-	-
Cashflow From Investing	315.2%	116	-53.80	-76.60	-749	1,785	-115	-82.10	-66.90	-219	-118	-16.80	236	-22.30	-58.70	-74.50	-145	-	-	-	-	-
Cashflow From Financing	-848.9%	-926	-97.60	-303	-974	-1,330	-758	-779	-1,009	-349	-877	-685	-1,099	149	-145	-584	-24.80	-	-	-	-	-
Dividend Payments	-	-	-	-	-	-	-	-	-	-	133	-	-	-	-	-	-	-	-	-	-	-
Buy Backs	-	-	-	-	250	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

VTRS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Net sales	$ 15,388.4	$ 16,218.1	$ 17,813.6
Total revenues	15,426.9	16,262.7	17,886.3
Cost of sales	8,988.3	9,765.7	12,310.8
Gross profit	6,438.6	6,497.0	5,575.5
Operating expenses:
Research and development	805.2	662.2	681.0
Acquired IPR&D	105.5	36.4	70.1
Selling, general and administrative	4,650.1	4,179.1	4,529.2
Litigation settlements and other contingencies, net	111.6	4.4	329.2
Total operating expenses	5,672.4	4,882.1	5,609.5
Earnings (loss) from operations	766.2	1,614.9	(34.0)
Interest expense	573.1	592.4	636.2
Other income, net	(9.8)	(1,790.7)	(5.8)
Earnings (loss) before income taxes	202.9	2,813.2	(664.4)
Income tax provision	148.2	734.6	604.7
Net earnings (loss)	$ 54.7	$ 2,078.6	$ (1,269.1)
Earnings (loss) per share attributable to Viatris Inc. shareholders
Basic (in USD per share)	$ 0.05	$ 1.71	$ (1.05)
Diluted (in USD per share)	$ 0.05	$ 1.71	$ (1.05)
Weighted average shares outstanding:
Basic (in shares)			1,208.8
Diluted (in shares)			1,208.8
Net sales
Revenues:
Net sales	$ 15,388.4	$ 16,218.1	$ 17,813.6
Other revenues
Revenues:
Other revenues	$ 38.5	$ 44.6	$ 72.7

VTRS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 991.9	$ 1,259.9
Accounts receivable, net	3,700.4	3,814.5
Inventories	3,469.7	3,519.5
Prepaid expenses and other current assets	2,028.1	1,811.2
Assets held for sale	2,786.0	230.3
Total current assets	12,976.1	10,635.4
Property, plant and equipment, net	2,759.6	3,024.5
Intangible assets, net	19,181.1	22,607.1
Goodwill	9,867.1	10,425.8
Deferred income tax benefit	692.9	925.9
Other assets	2,208.7	2,403.5
Total assets	47,685.5	50,022.2
Current liabilities:
Accounts payable	1,938.2	1,766.6
Income taxes payable	226.8	279.6
Current portion of long-term debt and other long-term obligations	1,943.4	1,259.1
Liabilities held for sale	275.1	0.0
Other current liabilities	3,393.9	3,440.9
Total current liabilities	7,777.4	6,746.2
Long-term debt	16,188.1	18,015.2
Deferred income tax liability	1,735.7	2,432.0
Other long-term obligations	1,516.9	1,756.5
Total liabilities	27,218.1	28,949.9
Viatris Inc. shareholders’ equity
Common stock: $0.01 par value, 3,000,000,000 shares authorized; shares issued: 1,221,994,491 and 1,213,793,231, respectively	12.2	12.1
Additional paid-in capital	18,814.7	18,645.8
Retained earnings	4,639.7	5,175.6
Accumulated other comprehensive loss	(2,747.4)
Stockholders Equity Parent Before Treasury Stock	20,719.2	21,072.3
Less: Treasury stock - at cost	251.8	0.0
Total equity	20,467.4	21,072.3
Total liabilities and equity	$ 47,685.5	$ 50,022.2

About Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

CEO	Mr. Scott Andrew Smith
WEBSITE	viatris.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	38000

Viatris Inc Frequently Asked Questions

What is the ticker symbol for Viatris Inc? What does VTRS stand for in stocks?

VTRS is the stock ticker symbol of Viatris Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Viatris Inc (VTRS)?

As of Tue Apr 23 2024, market cap of Viatris Inc is 13.49 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VTRS stock?

You can check VTRS's fair value in chart for subscribers.

What is the fair value of VTRS stock?

You can check VTRS's fair value in chart for subscribers. The fair value of Viatris Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Viatris Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VTRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Viatris Inc a good stock to buy?

The fair value guage provides a quick view whether VTRS is over valued or under valued. Whether Viatris Inc is cheap or expensive depends on the assumptions which impact Viatris Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTRS.

What is Viatris Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, VTRS's PE ratio (Price to Earnings) is 246.63 and Price to Sales (PS) ratio is 0.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VTRS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Viatris Inc's stock?

In the past 10 years, Viatris Inc has provided -0.136 (multiply by 100 for percentage) rate of return.